Budesonide Nebulization in Neonates

Clinical Context and Safety Concerns

The American Thoracic Society discourages routine corticosteroid use in neonates due to associated side effects and lack of long-term benefit, highlighting the need for caution with budesonide nebulization in this age group 1
In the context of bronchopulmonary dysplasia (BPD), uncontrolled data suggest inhaled steroids may improve lung mechanics and short-term outcomes in neonates, but the best dose, drug delivery device, and optimal timing are not known, and the side effect profile and long-term effects have not been determined 1
Echocardiography is recommended to assess cardiac structure and function in neonates with cardiomegaly and pulmonary findings, and chest imaging is necessary to better characterize the atelectasis and hyperaeration 1
Rule out infectious etiologies that may require antimicrobial therapy rather than corticosteroids in neonates with respiratory symptoms 1

Immediate cardiology consultation is necessary to evaluate cardiomegaly and determine if cardiac pathology is causing pulmonary findings in neonates 1
Supportive respiratory care, including oxygen, positioning, and gentle suctioning if needed, is recommended rather than pharmacologic anti-inflammatory therapy in neonates with respiratory symptoms 1

The American Journal of Respiratory and Critical Care Medicine guidelines note that systemic corticosteroids in early infancy are associated with decreased alveolar number, adverse neurologic outcomes, and cardiac complications including fatal cardiomyopathy 2, 3
The American Thoracic Society states that routine use of corticosteroids is discouraged in neonates due to associated side effects and lack of long-term benefit 4

At 2 months of age, the diagnosis of asthma cannot be reliably made, and respiratory symptoms are more likely due to other conditions, according to Praxis Medical Insights 4
For infants with bronchopulmonary dysplasia, inhaled steroids may be considered in specific NICU settings, but this requires specialized monitoring and is not applicable to routine outpatient use 4

If a 2-month-old has significant respiratory symptoms requiring anti-inflammatory therapy, this represents a complex clinical situation requiring specialist evaluation rather than empiric corticosteroid treatment 4
The potential for adrenal suppression, growth impairment, and other systemic effects is highest in the youngest patients, making risk-benefit considerations particularly unfavorable at 2 months of age 2, 3